The hospital demo went well. Clinicians asked thoughtful questions. A senior doctor offered to champion the product.
If your hospital demos in Asia-Pacific aren’t turning into purchase orders, the problem is often the buying pathway, not the product.
You left thinking: We’re getting somewhere.
Six months later, there’s still no purchase order.
The product works. Clinicians see its value. But demos, feedback and evaluations have not led to orders.
It is tempting to add another pilot, paper, distributor conversation or local hire. First ask: will it move a buyer closer to a decision?
A situation from prior industry experience
Before KawaHive was established, a medical device go-to-market project in an APAC market formed part of the professional experience behind this practice. The market reference has been generalised; no company, hospital, clinician or distributor is named. This is an example from our team’s previous industry experience, before KawaHive existed—not a KawaHive client engagement. Hospital demonstrations were booked, clinicians were engaged, and the distributor was optimistic.
The project team spent months pursuing hospitals that already had suppliers they trusted. Every evaluation seemed to end the same way:
The clinical feedback was positive, but that interest did not progress into a confirmed buying decision.
The team did not secure a purchase order.
The clinicians’ interest was genuine. But established suppliers already had the relationships, workflows and purchasing history, so those evaluations weren’t changing the hospital’s buying situation.
The project team then stepped back from the original approach and explored adjacent clinical applications. Over the next 12 months, the team spoke with clinicians, distributors and customers. The product didn’t change; the market strategy did.
When the company entered a different clinical segment, hospital demos began leading to buying discussions. Procurement came into view earlier, and tender specifications were eventually written around the product’s strengths.
That experience continues to shape how this practice approaches customer priorities, buying pathways and go-to-market execution in Asia-Pacific.
A positive evaluation is not the same as a buying pathway. Sometimes the product isn’t what needs to change. The route to market does.
When clinical evidence feels like progress
When a respected clinician says, “I’d love to publish a paper on this,” it feels like validation. It may be valuable. But ask: What decision will this information help someone make?
A paper can strengthen credibility without bringing a purchase any closer. A clinical champion may open doors, but they may not control the budget or the buying process.
Clinical evidence matters. So does knowing who needs to be persuaded, what they need to see, and what must happen between an evaluation and a purchase order. Clinical data is most useful when it helps the people involved in the purchase make a decision.
A good hospital demo is only the beginning
Hospitals don’t buy because one clinician says yes. They buy through a hospital procurement process involving multiple people, decisions and budgets.
The clinician may use the product. Department leaders build the case; technical teams assess requirements; procurement manages the process; and finance or hospital leadership approves the spend. Budgets may already be committed. Tender windows may be limited. Existing supplier contracts may still be active. Local service may be a prerequisite.
After a good hospital demo, don’t stop at “They liked it.” Find out who needs to be involved, what they need to decide, and when. Those answers help you tell the difference between interest and a credible path to purchase.
Before committing to another pilot, distributor or local hire
Prioritising another APAC country, appointing a distributor, hiring locally or launching another pilot all require time and capital. Before committing, pressure-test the go-to-market assumption behind the move: Will this bring a buyer closer?
In each target APAC market, understand how the hospital buying process works in the country and clinical segment you are prioritising. Public hospitals may use annual or multi-year tender cycles; private groups may follow different approval processes. Confirm that product registration remains valid for the target market, and assess local service expectations and procurement requirements. A go-to-market approach that works in one APAC country will not automatically transfer to another. Validate hospital buying pathways, procurement requirements and service expectations in each target market.
For a distributor, look beyond introductions and demos. Can they take an opportunity through procurement, installation, training and ongoing support?
For a local hire, ask whether you’re scaling a buying pathway that already works—or adding cost to a process that still depends on the founder.
And before launching another pilot, ask: Who will be closer to issuing a purchase order because this pilot happened? If the answer isn’t clear, consider what the pilot needs to prove—and who needs to act on the result.
An evaluation shows interest. A purchase order shows willingness to buy. Repeat purchases suggest you’re building a route to market you can scale.
Country examples: where to check procurement requirements
Public-sector purchasing routes differ by country and institution. These official sources illustrate the types of local checks a supplier should make; they do not replace the tender documents or the hospital's own procurement guidance.
- Malaysia: MDA Circular Letter No. 1/2026, effective 28 January 2026, requires new medical-device tenderers to hold a valid establishment licence, implement GDPMD and accept post-market responsibilities; healthcare institutions must verify the tenderer's licence, the product's valid registration and the distributor appointment letter. MDA's 5 March 2026 implementation notice sets limited transition exemptions for specified pre-28 January contracts and tenders. Check both the MDA Circular Letter and its implementation notice, plus current Ministry of Health tenders.
- Singapore: The Ministry of Finance's procurement guidance, updated 9 September 2026, sets out Small Value Purchases up to S$6,000, quotations up to S$90,000 and tender procedures above S$90,000, subject to the stated rules and exceptions. Notices and opportunities are published through GeBIZ. Check the current MOF procurement process and the specific agency documents.
- New South Wales, Australia: HealthShare NSW manages statewide contracts that include medical equipment. Its guidance says products do not need to be listed in the National Product Catalogue before a state tender response, but catalogue publication is mandatory for most health-specific medical/surgical device and consumable contracts before the agreement starts. Confirm the relevant contract and supplier requirements.
For the account in front of you, confirm the actual route: tender, quotation, panel or contract, private-group approval, or another purchasing pathway. Identify who owns the clinical evaluation, technical review, budget and final purchase decision.
A five-step hospital buying pathway
After a positive evaluation, use these questions to find the gap between clinical interest and a purchase decision:
- Clinical interest: Who sees the value, and what problem do they need the product to solve?
- Buying process: Who else must assess, recommend or approve the purchase?
- Purchase conditions: What budget, clinical data, tender, technical, service or training requirements remain?
- Accountable next step: Who will do what, and by when? Record an owner and date rather than “follow up”.
- Buying signals: What observable event would show progress, such as a procurement meeting, quote request, confirmed budget or tender inclusion?
Not every evaluation should convert. A useful outcome may be learning that the budget, timing or clinical case is not strong enough. Record what you learned and decide whether to continue, pause or redirect effort.
How to tell hospital interest from a real purchase order
Clinical interest is valuable. Purchase orders are the clearest buying signal.
The challenge isn’t to dismiss clinical enthusiasm or clinical findings. It’s to connect them to a repeatable path from evaluation to procurement, and from procurement to paid adoption—in the target APAC market.
If you’ve run dozens of hospital demos without purchase orders, you may not need more demos yet. Start by understanding what’s blocking the buying decision: budget timing, tender requirements, an incumbent supplier, distributor capability or something else.
If you’re assessing a target APAC market, distributor or pilot for a product already registered there, KawaHive helps founders in the MedTech and medical devices sector pressure-test the GTM approach before committing further time and capital.
Bring one real hospital procurement, target-account or distributor challenge. We’ll help you identify where the path from clinical interest to procurement is getting stuck.